Author

Adama Ouiminga

Observed names: A Ouiminga, A. Ouiminga

Observed institutions: Inserm, Agence Nationale de Recherches sur le Sida et les Hépatites Virales, Centre Muraz

OpenAlex ID: A5086153111

Factors predicting uptake of voluntary counselling and testing in a real‐life setting in a mother‐and‐child center in Ouagadougou, Burkina Faso

2006 · Salvatore Pignatelli, Jacques Simpore, et al. · Tropical Medicine & International Health · 64

Spoligotyping ofMycobacterium africanum, Burkina Faso

2012 · Michel K. Gomgnimbou, Guislaine Refrégier, et al. · Emerging infectious diseases · 32

PDF

A novel pharmacokinetic approach to predict virologic failure in HIV-1-infected paediatric patients

2012 · Naïm Bouazza, Jean-Marc Tréluyer, et al. · AIDS · 13

Pharmacology and immuno-virologic efficacy of once-a-day HAART in African HIV-infected children: ANRS 12103 phase II trial

2011 · Boubacar Nacro, Emmanuelle Zoure, et al. · Bulletin of the World Health Organization · 11

PDF

2010 · Naïm Bouazza, Déborah Hirt, et al. · Antimicrobial Agents and Chemotherapy · 10

Didanosine Population Pharmacokinetics in West African Human Immunodeficiency Virus-Infected Children Administered Once-Daily Tablets in Relation to Efficacy after One Year of Treatment

2009 · Déborah Hirt, Christophe Bardin, et al. · Antimicrobial Agents and Chemotherapy · 10

Short-Term Virological Efficacy, Immune Reconstitution, Tolerance, and Adherence of Once-Daily Dosing of Didanosine, Lamivudine, and Efavirenz in HIV-1–Infected African Children: ANRS 12103 Burkiname

2011 · Makoura Barro, Jérôme Some, et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 8

24-Month adherence, tolerance and efficacy of once-a-day antiretroviral therapy with didanosine, lamivudine, and efavirenz in African HIV-1 infected children: ANRS 12103/12167

2013 · H Hien, N Meda, et al. · African Health Sciences · 5

PDF

Spoligotyping of Mycobacterium africanum

2012 · Burkina Faso, Michel Kiréopori Gomgnimbou, et al. · 4

Once-a-day pediatric HAART with DDI+3TC+EFV in Burkina Faso. A phase II trial (ANRS 12103 trial)

2008 · Philippe Msellati, Boubacar Nacro, et al. · Retrovirology · 3

PDF

Feasibility and efficacy of HAART among hard-to-reach high-risk women in Burkina Faso

2008 · C. Huët, Abdoulaye Ouédraogo, et al. · 2

Feasibility and efficacy of highly active antiretroviral therapy among high-risk and marginalised HIV-1 infected women in West Africa.

2009 · C. Huët, Nomtondo Amina Ouédraogo, et al. · 1

Modeling plasma virions and CD4+lymphocytes kinetics in HIV-1 infected children related to three drug exposures : efavirenz-didanosine-lamivudine

2012 · Naïm Bouazza, Philippe Msellati, et al. · Fundamental and Clinical Pharmacology

Mycobacterium africanum did not disappear from Burkina Faso

2011 · Michel Kiréopori Gomgnimbou, Guislaine Refrégier, et al. · F1000Research

Pharmacology and immuno-virologic efficacy of once-a-day HAART in African HIV-infected children: ANRS 12103

2011 · Hervé Hien, François Rouet, et al.

Adherence in HIV-1 infected children taking once daily HAART with Didanosine + Lamivudine + Efavirenz in West Africa. ANRS 12103 clinical trial

2009 · Jerôme Somé, Boubacar Nacro, et al. · Retrovirology

PDF

Didanosine population pharmacokinetics in West African HIV-infected children administered once daily tablets in relation to efficacy after one year of treatment (ANRS 12103)

2009 · Déborah Hirt, Christophe Bardin, et al. · Retrovirology

PDF

Evolution of the biological follow-up of efficiency and tolerance of a once daily antiretroviral treatment with 3TC+DDI+EFV in children infected with HIV-1 (CLINICAL TRIAL ANRS 12 103)

2009 · Boubacar Nacro, Yaya Diasso, et al. · Retrovirology

PDF

Works count: 20

Citation count: 163

H-index: 7

I10-index: 6